Literature DB >> 29237896

Microwave ablation: Results with three different diameters of antennas in ex vivo bovine and in vivo porcine liver.

Ze Song1, Han Qi1, Hao Zhang2, Lin Xie1, Fei Cao1, Weijun Fan1, Chao Wan3.   

Abstract

PURPOSE: To evaluate the ablation ranges and temperature rising rates of three microwave antenna with different diameters in vitro bovine and in vivo porcine livers.
MATERIALS AND METHODS: In vitro and in vivo study, microwave ablations (MWA) were induced at a power output of 70 W for 5, 8, and 10 min; a total of 54 and 36 ablations were performed, respectively. Temperature measurements were performed in the 70 W/10 min group with 3 different microwave antennas.
RESULTS: In vitro study, the long axis diameter for the 16G microwave antenna was longer than the 15G (P < 0.05) and 14G microwave antennae (P < 0.05). The sphericity index for the 14G and 15G microwave antennae was higher than the 16G microwave antenna (P < 0.05 for both). In the in vivo study, the short- and long-axis diameters, and sphericity index were not statistically different between the 14G, 15G, and 16G groups. The temperature data were not statistically different in both studies.
CONCLUSIONS: Although the thin microwave antenna had a longer long-axis diameter and a lower sphericity index in vitro study, the thin microwave antenna achieved the same ablation effect in vivo application. MWA has several advantages, and the thin microwave antenna decreases the puncture risk and complication rate. Thus, a thin microwave antenna (15G and 16G) is beneficial in clinical applications and will have a significant influence in the development of MWA.

Entities:  

Mesh:

Year:  2017        PMID: 29237896     DOI: 10.4103/jcrt.JCRT_755_17

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.

Authors:  Yang Ni; Xin Ye; Xia Yang; Guanghui Huang; Wenhong Li; Jiao Wang; Xiaoying Han; Zhigang Wei; Min Meng
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-10       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.